Bioxcel therapeutics announces positive topline results from tranquility ii phase 3 trial of bxcl501 for acute treatment of alzheimer's disease-related agitation

Trial met primary endpoint with the 60 mcg dose, with bxcl501 demonstrating a statistically significant 39% greater reduction in pec score from baseline compared to placebo at 2 hours (p=0.0112)

BTAI Ratings Summary

BTAI Quant Ranking